Proto Script Pharmaceutical logo

Proto Script Pharmaceutical(OTC) PSCR

Market Cap$5.70KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2016)-100%
5 Year-95%
1 Year+0%
1 Month-50%
$0.00
+0.00%
+0.00Today
Proto Script Pharmaceutical last closing stock price
MetricPriceDate
Last closeUSD 0.002026-08-26
Proto Script Pharmaceutical stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-50%USD 0.002026-06-09
1 month-50%USD 0.002026-06-09
3 month-50%USD 0.002026-05-26
Year to date+0%USD 0.002025-12-09
1 year+0%USD 0.002025-08-07
3 year-98%USD 0.012023-08-22
5 year-95%USD 0.002021-08-27
Since inception-99.92%USD 0.132016-08-22

Proto Script Pharmaceutical Financials at a Glance

Market Cap

$5.70KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$604.98K

Net Income (TTM)

-$8.39M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

29.71 (High)

Price

$0.00

Volume

21,600

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

N/A

PSCR News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Proto Script Pharmaceutical

Proto Script Pharmaceutical Corp. is a California-based company specializing in the maintenance and rental of power wheelchairs and scooters. Established in 2001, the firm primarily serves federal, state, and private insurance providers.

Products and Services
  • Maintenance and rental of power wheelchairs
  • Rental services for mobility scooters
  • Support for insurance providers in mobility solutions
Growth Outlook
  • Revenue increased to $251,974 in Q3 2017, showing potential for growth
  • Gross profit margin improved to 84.84% in Q3 2017
  • Operating cash flow indicates a focus on operational efficiency
Financial Highlights
  • Trailing twelve months (TTM) revenue of $504,000
  • Net income for Q3 2017 was -$283,653, reflecting ongoing challenges
  • Current ratio at 0.30 indicates liquidity concerns
Proto Script Pharmaceutical Corp. operates in a niche market, providing essential mobility solutions. The company has demonstrated a significant gross profit margin, indicating effective cost management in its operations. However, the net income figures highlight ongoing financial challenges that may require strategic adjustments. The recent revenue growth suggests a potential upward trend, which could attract investor interest. The current ratio indicates liquidity issues, emphasizing the need for careful financial management moving forward. Overall, Proto Script Pharmaceutical Corp. presents a unique opportunity within the specialty business services sector, particularly for those interested in the healthcare and mobility solutions market.
AI Generated • Sep 23, 2026

Industry

Healthcare Providers and Services

Headquarters

Rancho Cucamonga, CA 91730, US

PSCR Financials

Key Financial Metrics (TTM)

Gross Margin

71.55%

Operating Margin

-37.78%

Net Income Margin

-910.40%

Return on Equity

5578.94%

Return on Capital

N/A

Return on Assets

-4220.39%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

-0.83%

Stock Overview

Market Cap

$5.70KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

56.90M

Volume

21.60K

Avg. Volume

332.308

Financials (TTM)

Gross Profit

$351.81K

Operating Income

-$970.95K

EBITDA

-$845.20K

Operating Cash Flow

-$303.10K

Capital Expenditure

-$33.85K

Free Cash Flow

-$336.94K

Cash & ST Invst.

$0.00

Total Debt

$372.75K

Proto Script Pharmaceutical Performance Analysis

Proto Script Pharmaceutical sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42016-12-31-53.1%
Q12017-03-3137.8%
Q22017-06-30-17.3%
Q32017-09-30120.3%
Proto Script Pharmaceutical sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42016-12-31-4878456.2%
Q12017-03-3195.6%
Q22017-06-30-100.0%
Q32017-09-3014.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name
Q3 2017YOY CHG

Revenue

$251.97K

+17.8%

Gross Profit

$213.78K

+22.6%

Gross Margin

84.84%

N/A

Market Cap

$5.70KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$438.46

N/A

Employees

13

N/A

Net Income

-$283.65K

-190471.1%

EBITDA

-$163.56K

-11892.0%

Quarterly Fundamentals

Name
Q3 2017YOY CHG

Total Cash

$0.00

-100.0%

Total Debt

$372.75K

+353.3%

Accounts Receivable

$166.44K

-32.7%

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$372.75K

+353.3%

Return on Assets

-42.20%

N/A

Return on Invested Capital

93.23%

N/A

Free Cash Flow

-$24.90K

+39.6%

Operating Cash Flow

-$24.30K

+36.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
AMCTAmerican Education Center, Inc.
$0.00+0.00%
MHHCMHHC Enterprises, Inc.
$0.00+0.00%
XREGXR Energy, Inc.
$0.00+0.00%
OLNKOneLink Corporation
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$107.08-5.34%
NVDANvidia
$230.48-2.94%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$33.79+10.24%
BITOProShares Trust - ProShares Bitcoin ETF
$10.93-1.88%

Questions About PSCR

What is the current price of Proto Script Pharmaceutical?

Proto Script Pharmaceutical is trading at $0.00 per share.

What is the 52-week range for Proto Script Pharmaceutical?

Over the past 52 weeks, Proto Script Pharmaceutical has traded between $0.00 and $0.00.

How much debt does Proto Script Pharmaceutical have?

Proto Script Pharmaceutical total debt is unavailable.

How much cash does Proto Script Pharmaceutical have on hand?

Proto Script Pharmaceutical does not have cash on hand data available.

What is Proto Script Pharmaceutical’s dividend yield?

Proto Script Pharmaceutical does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.